Addex Therapeutics Ltd - Company Profile
Powered by 
All the data and insights you need on Addex Therapeutics Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Addex Therapeutics Ltd Strategy Report
- Understand Addex Therapeutics Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Addex Therapeutics Lead Sheet
Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Addex Therapeutics Ltd’s relevant decision makers and contact details.
A sample of Addex Therapeutics Lead Sheet data
| Lead Date | Lead Type | Lead Description | Company Name | Drug Name | Therapy Area |
|---|---|---|---|---|---|
| 26 Jul 2022 | GDCTWXYZ | Lorem | Lorem | Lorem | Cardiovascular |
| 22 Jul 2022 | Capital Raisings | Addex Therapeutics (Addex) to Raise USD4.2 million in Equity Financing | Addex Therapeutics Ltd | ADX-71441; ADX-71743; ADX-88178; dipraglurant; dipraglurant ER; dipraglurant IR; M4 PAM; mGlu2 NAM; MGlu3 PAM; Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders | Cardiovascular; Central Nervous System; Genetic Disorders; Genito Urinary System And Sex Hormones; Ophthalmology |
| 20 Jul 2022 | Capital Raisings | Addex Therapeutics to Raise Funds through Public Offering of Shares | Addex Therapeutics Ltd | ADX-1; ADX-3; ADX-4; ADX-5; ADX-50938; ADX-6; ADX-63365; ADX-68692; ADX-68693; ADX-71441; ADX-71743; ADX-71943; ADX-85142; ADX-88178; ADX-92639; ADX-94819; dipraglurant; dipraglurant ER; dipraglurant IR; M4 PAM; mGlu2 NAM; MGlu3 PAM; Small Molecule to Agonize A2A for Hematological, Immunology and Neurological Disorders; Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health; Small Molecule to Inhibit FSHR/LHR For Sex Hormone Dependent Tumors; Small Molecules for Obesity; Small Molecules to Agonize GLP1R for Type 2 Diabetes; Small Molecules to Agonize MGLUR8 for Central Nervous System Disorders; Small Molecules to Agonize TRKB for Neurodegenerative Diseases; Small Molecules to Antagonize IL-1 Receptor for Metabolic Disorders; Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders; Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders; Small Molecules to Target GIPR for Type 2 Diabetes; Small Molecules to Target HCRTR2 for Sleep Disorders | Cardiovascular; Central Nervous System; Gastrointestinal; Genetic Disorders; Genito Urinary System And Sex Hormones; Hematological Disorders; Immunology; Male Health; Metabolic Disorders; Musculoskeletal Disorders; Non Malignant Disorders; Oncology; Ophthalmology; Respiratory; Women's Health |
| 03 Jun 2022 | Expected Trial Results | Phase II/III Top-line Results Expected in H1-2023 | Addex Therapeutics Ltd | dipraglurant IR | Central Nervous System |
Feature
Lead Sheet offers business development users in a Supplier Company, convenient access to leads within the biopharmaceutical industry.
- Lead: Any current or future events that signal a company may need services from another company in the near future.
Depending on the user’s company type, specific events may be considered a lead for the goods or services they provide.
Benefit
Leads within Lead Sheet fall into six major types of occurrences: Trial Events, Regulatory Events, Deals, Insights, New Companies, and Role Changes.
Some of these categories are broken out further to allow users the flexibility to filter to the event types they consider a lead.
Any lead type starting with “Expected” implies that it is a future event sourced from our Catalyst Calendar.
Value
Lead Sheet is a business development tool to help optimize sales efficiency
- What prospective accounts to target
- When and why to target them through actionable leads/opportunities
- Who to reach out to
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer